A new weapon to boost cancer immunotherapy

In recent years, immuno-oncology has become one of the leading methods of cancer treatment. Immunotherapy stimulates the immune system to destroy tumours more effectively and can be used in combination with other therapies or surgery. Now, scientists are finding ways to refine immunotherapy through enhancing the tumour cell immunogenicity, increasing the number of immune cells at the tumour site, or by blocking specific molecules which cancer cells produce to suppress the immune system’s attack on the tumour.

One particularly exciting immunotherapy combination approach has been discovered by the Research and Translational Medicine group at 4SC, headed by Dr Svetlana Hamm. Along with her team, she is exploring the potential of an HDAC (histone deacetylase) inhibitor called domatinostat. Domatinostat works in conjunction with immunotherapy, specifically one that targets the PD-1/PD-L1 axis (programmed death protein 1 and PD-Ligand 1), with the aim to reestablish the immune system’s attack on the tumour.

**CANCER IMMUNITY AND THE PD-1/PD-L1 AXIS**

Genetic mutations in cells can result in a dysregulation of cellular processes and uncontrolled cell proliferation, eventually causing tumourigenesis. On the other hand, mutations and dysregulated gene expression can cause tumour cells to produce tumour antigens and release signals, marking them as foreign to the immune system. Depending on how visible this process is to the body, the immune system will respond and eliminate such cells. However, often cancer cells remain unnoticed or manage to block the immune attack.

The immune response generally involves an influx of specific cells of the immune system, so-called cytotoxic T cells (CTLs) to the tumour site. These cells specifically kill tumour cells through recognition of their tumour antigens. However, tumour cells can block this attack by upregulating the PD-L1 molecule on the surface. PD-L1 binds to the inhibitory PD-1 receptor expressed on CTLs, blocking their activity and rendering them essentially useless. The so-called checkpoint blockade is one form of immunotherapy which stops the PD-L1 molecule from binding to the CTL’s PD-1 receptor, thereby unleashing the CTL attack on the tumour cells. As successful as this approach has been in many cases, responses in patients vary greatly between different cancer types and between individual patients. This can be due to the absence of a tumour-specific immune response, downregulation of tumour-specific antigen presentation, or immunosuppressive cells and molecules produced by the cancer cells to inhibit CTL function, independently of the action of PD-L1.

**CANCER CELLS HAVE MANY DEFENCE MECHANISMS**

Tumours can display different levels of immune system involvement. ‘Hot’ tumours have CTLs present in the tumour immune microenvironment but are actively expressing PD-L1 as a defence to suppress the CTL attack (see figure 1, panels 2, 3, and 4). ‘Cold’ tumours do not have immune cells in their microenvironment and likely have avoided immune detection, so there is no need for these tumour cells to upregulate PD-L1 (panel 1). In this case, the aim of the therapy is to ‘heat-up’ the tumour and cause CTLs to infiltrate. Checkpoint inhibitors can then contribute to the tumour-specific immune response by blocking the PD-1/PD-L1 interaction, resulting in the killing of cancer cells (panel 2).

Unfortunately, tumours fight back. Tumour cells try to avoid recognition and binding by CTLs through downregulation of antigen presentation, or immunosuppressive cells and molecules produced by the cancer cells to inhibit CTL function. Two of the drugs proposed to target this pathway are HDAC inhibitors, which increase expression of tumour antigens and their presentation to CTLs, as well as the number of CTLs in the tumour immune microenvironment via production of cellular signals attracting immune cells to the tumour.

Domatinostat, which is a specific HDAC inhibitor, has previously been tested and showed promising anti-cancer activity as monotherapy. Given the varied effectivity of PD-1/PD-L1 blockers, the first step was to test domatinostat on mice bearing tumour types with varying CTL levels (‘hot’ or ‘cold’) tumours. The mice were then treated with domatinostat and PD-1/ PD-L1 blockers (mouse-specific analogues of established human checkpoint inhibitors like nivolumab, pembrolizumab, or avelumab). The results were clear. In the cold CT26 tumours, domatinostat alone decreased the tumour size by half and increased the number of CTLs by eightfold (see figure 2). Furthermore, the treatment triggered the immune-related cellular machinery, enhancing inflammation and turning the tumour into an ‘active’ one, which also increased the recognisability of tumour cells to the CTLs by upregulating the production of tumour antigens and their presentation on the cell surface.

When a combination of domatinostat and PD-1/PD-L1 blockers was administered, thesynergistic effect was increased further, whereas PD-1/PD-L1 blockers alone were not effective.

**Domatinostat aims to restart the immune system’s attack on the tumour and works in conjunction with immunotherapy, specifically one that targets the PD-1/PD-L1 axis.**

PD-L1 blockade dependent on the microenvironment, Dr Hamm and her team at 4SC proposed that the addition of domatinostat would combat cancer defects causing resistance to checkpoint therapy.

**TESTING DOMATINOSTAT IN TUMOUR-BEARING MICE**

The first step was to test domatinostat on mice bearing tumour types with varying CTL levels (‘hot’ or ‘cold’) tumours. The mice were then treated with domatinostat and PD-1/ PD-L1 blockers (mouse-specific analogues of established human checkpoint inhibitors like nivolumab, pembrolizumab, or avelumab). The results from the hot C38 tumour model were similarly impressive. Although C38 tumours already accommodate a high number of CTLs, these cells are not able to eliminate the tumours because of their exhausted state. Consequently, blockade of PD-1/PD-L1 alone has only a minor effect in this type of cancer. Domatinostat, however, managed to increase the number of CTLs in these tumours by nearly twofold, and more importantly, also increased their activity and effectivity. As a result, a greatly increased survival time was observable.
Behind the Research
Dr Svetlana Hamm

Research Objectives

Dr Hamm and her team are examining the HDAC inhibitor domatinostat and its ability to increase anti-tumour efficacy of immunotherapies.

Detail

Bio
Dr Svetlana Hamm has been working in the area of cancer immunology for more than 15 years. She is Head of Research and Translational Medicine at 4SC. 4SC, a biotech company in the South of Germany, is developing new therapies supporting the patient’s immune system with the aim to change the way cancers will be treated in future, providing lasting responses and definitive cure.

References


Personal Response

What did the toxicity profile look like in the patients tested so far?

Domatinostat alone, as well as in combination with pembrolizumab, was safe and well-tolerated in patients. So far, only a few severe treatment-related adverse events have been observed and the SENSITIZE trial continues to recruit patients. Additionally, domatinostat is under evaluation in further clinical trials testing the combination of domatinostat with checkpoint inhibitors in patients with colorectal and gastric cancer or with MCC that is relapsed or refractory to checkpoint inhibitor therapy.

Domatinostat, in combination with pembrolizumab, has been shown to achieve high response rates in patients with melanoma who are not responding to prior checkpoint inhibitor therapy. The combination has shown promising results in terms of clinical benefit and safety, and further studies are ongoing to explore its potential as a therapy for other cancer types.

Domatinostat consistently improved the tumour immune microenvironment’s composition to maximise the potential for successful PD-1/PD-L1 blockade treatment.

is an ongoing clinical trial, looking at patients with melanoma who are not responding to checkpoint blockade alone – the ideal setup for domatinostat (Hassel et al., 2019).

In this trial, domatinostat is given as monotherapy for two weeks before checkpoint blockade is added. The 4SC team monitors the expression of relevant genes in the tumours of patients before and after administration of domatinostat. They observed increased expression of cancer antigens, antigen presenting machinery and enhanced inflammation in the first patients evaluated, which confirms the observations from the prior animal tests, and implies an increased susceptibility to the subsequent treatment with checkpoint inhibitors.

FROM BENCH TO BEDSIDE

Domatinostat has proved itself in these early tests to be a very effective combination partner for PD-1/PD-L1 inhibitors. As described above it accomplishes this by not only increasing CTL count in the tumour microenvironment, but also by enhancing CTL activity and effectivity, and activating immune pathways which combat the cancer cell resistance mechanisms. These effects are expected to be particularly useful in cancers like melanoma, Merkel cell carcinoma (MCC), urothelial cancer, and colorectal carcinoma.

These early biomarker results for domatinostat therapy from the SENSITIZE trial are very encouraging and the whole 4SC team is looking forward to continuing development of this potentially practise-changing drug for combination immunotherapy.

ADDITION TO THE COCKTAIL

MHC-II (major histocompatibility complex-II) molecules are proteins present on the surface of cells. They support the generation of additional tumour-specific CTL types, thereby enhancing the immune attack on the tumour. Domatinostat has been shown to increase MHC-II molecules in tumours. However, this beneficial effect on the immune response generation is often found to be levelled out by a negative effect on CTL activity due to the binding of MHC-II to another inhibitory CTL receptor LAG3, which blocks the function of CTLs similarly to PD-1. Thus, in another experiment with tumour-bearing mice, Dr Hamm and her team at 4SC added a LAG3 blocker to the mix of domatinostat and PD-1/PD-L1 blockade. This resulted in even higher anti-tumour activity, with the tumour regressing in 80% of the animals tested.

Another important component in this context is a cellular molecule called 4-1BB, which is a co-stimulatory receptor for CTLa. Co-stimulation is a mechanism required by CTLs to become fully effective. 4-1BB encourages CTL proliferation, and when CTLs are exhausted, co-stimulatory receptors like 4-1BB can partly restore their cell-killing capabilities. Indeed, co-stimulation of 4-1BB was found to be more effective than PD-1/PD-L1 blockade, with a response rate of 35% in these hard to treat T cell-exhausted tumours. Remarkably, when domatinostat was added, the response rate doubled to 70%.

THE SENSITIZE TRIAL

The next step was to test domatinostat on human patients. The SENSITIZE trial is an ongoing clinical trial, looking at patients with melanoma who are not responding to prior checkpoint inhibitor therapy. The trial is investigating the potential of domatinostat as a monotherapy for two weeks before checkpoint blockade is added. The 4SC team monitors the expression of relevant genes in the tumours of patients before and after administration of domatinostat. They observed increased expression of cancer antigens, antigen presenting machinery and enhanced inflammation in the first patients evaluated, which confirms the observations from the prior animal tests, and implies an increased susceptibility to the subsequent treatment with checkpoint inhibitors.

Domatinostat strongly increases the number of CTLs in the tumour (on the right) compared to the untreated tumours (on the left).

Figure 2: The infiltration of CTLs into the tumour can be analysed by staining these cells with specific colours. Here, tumour cells are blue and CTLs are brown. Domatinostat strongly increases the number of CTLs in the tumour (on the right) compared to the untreated tumours (on the left).